These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 38390628)
21. Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors. Mizukami S; Kajiwara C; Ishikawa H; Katayama I; Yui K; Udono H Cancer Sci; 2008 May; 99(5):1008-15. PubMed ID: 18341654 [TBL] [Abstract][Full Text] [Related]
22. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. Kissick HT; Sanda MG; Dunn LK; Arredouani MS PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990 [TBL] [Abstract][Full Text] [Related]
23. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612 [TBL] [Abstract][Full Text] [Related]
24. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
25. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Snook AE; Magee MS; Schulz S; Waldman SA Eur J Immunol; 2014 Jul; 44(7):1956-66. PubMed ID: 24771148 [TBL] [Abstract][Full Text] [Related]
26. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy. Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722 [TBL] [Abstract][Full Text] [Related]
27. Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147 [TBL] [Abstract][Full Text] [Related]
28. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034 [TBL] [Abstract][Full Text] [Related]
29. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer. NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665 [TBL] [Abstract][Full Text] [Related]
30. CD4 Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929 [TBL] [Abstract][Full Text] [Related]
31. Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes. Domínguez-Romero AN; Martínez-Cortés F; Munguía ME; Odales J; Gevorkian G; Manoutcharian K Immunology; 2020 Oct; 161(2):123-138. PubMed ID: 32619293 [TBL] [Abstract][Full Text] [Related]
33. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model. Simons BW; Cannella F; Rowley DT; Viscidi RP Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503 [TBL] [Abstract][Full Text] [Related]
34. In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients. Chai SJ; Fong SCY; Gan CP; Pua KC; Lim PVH; Lau SH; Zain RB; Abraham T; Ismail SM; Abdul Rahman ZA; Ponniah S; Patel V; Cheong SC; Lim KP Hum Vaccin Immunother; 2019; 15(1):167-178. PubMed ID: 30193086 [TBL] [Abstract][Full Text] [Related]
35. The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion. Zhang Y; Ertl HC J Immunol; 2014 Aug; 193(4):1836-46. PubMed ID: 25024391 [TBL] [Abstract][Full Text] [Related]
36. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cesson V; Rivals JP; Escher A; Piotet E; Thielemans K; Posevitz V; Dojcinovic D; Monnier P; Speiser D; Bron L; Romero P Cancer Immunol Immunother; 2011 Jan; 60(1):23-35. PubMed ID: 20857101 [TBL] [Abstract][Full Text] [Related]
37. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104 [TBL] [Abstract][Full Text] [Related]
38. Personalized cancer vaccination in head and neck cancer. Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875 [TBL] [Abstract][Full Text] [Related]